Brochure | February 22, 2021

IBC And Consulting Services

Source: Advarra

Study startup is already a challenging process, with researchers juggling study activation goals, accrual rates, and endpoints. Why add the complication of IBC reviews that take more than a month to complete?

Advarra’s standard IBC review turnaround time is 10 business days or less. In a case study of 52 consecutive IBC submissions for NCI-designated cancer centers, we completed reviews in an average of 6.5 business days. Across 65 COVID-19 trials, we completed reviews in an average of 4.1 business days.

The less time it takes to complete IBC reviews, the more attractive sites are to industry sponsors and CROs—and the faster patients can gain access to clinical trials.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader